HIKMA Pharmaceuticals PLC — Audit Report / Information 2014

Sep 18, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5565Z

Hikma Pharmaceuticals Plc

18 September 2015

Hikma Pharmaceuticals PLC

Audit Tender Process

LONDON, 18 September 2015 - Hikma Pharmaceuticals PLC (the "Company") announces that, following a formal tender process for its statutory audit contract, which was initiated in line with current corporate governance best practice, the Board have approved the proposed appointment of PricewaterhouseCoopers LLP as the Company's new statutory auditors, subject to approval by shareholders at the 2016 AGM. Deloitte LLP will therefore stand down as the Company's auditors at the conclusion of the 2016 AGM.

Pat Butler, Chairman of the Audit Committee, said: "On behalf of the Board, I would like to thank Deloitte LLP for their significant contribution to Hikma since listing in 2005 and before that as a private company."

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	+44 20 7399 2670
Susan Ringdal VP, Corporate Strategy and Investor Relations	+44 20 7399 2670

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPKFDNNBKDFCD